MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
A PHASE 1B/2, OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA) CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH OTHER ANTI-CANCER TREATMENTS IN PARTICIPANTS WITH MULTIPLE MYELOMA
Sponsor: Pfizer
Terminated
A business decision was made by Pfizer to terminate the study and not proceed with the Phase 2 expansion of this study. The reason for study termination is not due to any safety concerns or requests from regulatory authorities.
A observational or N/A phase clinical study on Multiple Myeloma, this trial is terminated or withdrawn. The trial is conducted by Pfizer and has accumulated 34 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
34 versions recorded-
Apr 28, 2026 — Present [daily]
Terminated
Status: Active Not Recruiting → Terminated · Phase: PHASE2 → None
-
Feb 2026 — Apr 2026 [monthly]
Active Not Recruiting PHASE2
-
Dec 2025 — Feb 2026 [monthly]
Active Not Recruiting PHASE2
-
Nov 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE2
-
Oct 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE2
▶ Show 29 earlier versions
-
Sep 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE2
-
Jul 2025 — Aug 2025 [monthly]
Recruiting PHASE2
-
Jun 2025 — Jul 2025 [monthly]
Recruiting PHASE2
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE2
-
Apr 2025 — May 2025 [monthly]
Recruiting PHASE2
-
Feb 2025 — Apr 2025 [monthly]
Recruiting PHASE2
-
Dec 2024 — Feb 2025 [monthly]
Recruiting PHASE2
-
Sep 2024 — Dec 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
Feb 2024 — May 2024 [monthly]
Recruiting PHASE2
-
Nov 2023 — Feb 2024 [monthly]
Recruiting PHASE2
-
Sep 2023 — Nov 2023 [monthly]
Recruiting PHASE2
-
Jul 2023 — Sep 2023 [monthly]
Recruiting PHASE2
-
Jun 2023 — Jul 2023 [monthly]
Recruiting PHASE2
-
May 2023 — Jun 2023 [monthly]
Recruiting PHASE2
-
Apr 2023 — May 2023 [monthly]
Recruiting PHASE2
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE2
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE2
-
Jan 2023 — Feb 2023 [monthly]
Recruiting PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Recruiting PHASE2
-
Nov 2022 — Dec 2022 [monthly]
Recruiting PHASE2
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE2
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE2
-
Apr 2022 — Jul 2022 [monthly]
Recruiting PHASE2
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE2
Phase: PHASE1_PHASE2 → PHASE2
-
Dec 2021 — Mar 2022 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting · Phase: PHASE2 → PHASE1_PHASE2
-
Nov 2021 — Dec 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Oct 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
The purpose of this study is to determine the Recommended Phase 2 Dose and clinical benefit of elranatamab in combination with other anti-cancer therapies in participants with multiple myeloma.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .